Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

The placebo response in pain and depression: in search of a common pathway.

Wernicke JF, Ossanna MJ.

Front Biosci (Schol Ed). 2010 Jan 1;2:106-11. Review.

PMID:
20036932
2.

Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients.

Wasan AD, Ossanna MJ, Raskin J, Wernicke JF, Robinson MJ, Hall JA, Edwards SE, Lipsius S, Meyers AL, McCarberg BH.

Curr Drug Saf. 2009 Jan;4(1):22-9.

PMID:
19149522
3.

Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions.

Wernicke JF, Prakash A, Kajdasz DK, Houston J.

J Diabetes Complications. 2009 Sep-Oct;23(5):349-59. doi: 10.1016/j.jdiacomp.2008.07.004. Epub 2008 Sep 2.

PMID:
18768332
4.

Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources.

Strombom I, Wernicke JF, Seeger J, D'Souza DN, Acharya N.

Curr Drug Saf. 2008 May;3(2):154-62.

PMID:
18690993
5.

Answers to the most common questions about the hepatic safety profile of duloxetine.

Wohlreich MM, Acharya N, Strombom I, Kuritzky L, Robinson M, Heinloth AN, Regev A, Wernicke JF.

Postgrad Med. 2008 Jul;120(2):111-8. doi: 10.3810/pgm.2008.07.1803. Review.

PMID:
18654076
6.

Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder.

Bangs ME, Jin L, Zhang S, Desaiah D, Allen AJ, Read HA, Regev A, Wernicke JF.

Drug Saf. 2008;31(4):345-54.

PMID:
18366245
7.

Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials.

Arnold LM, Pritchett YL, D'Souza DN, Kajdasz DK, Iyengar S, Wernicke JF.

J Womens Health (Larchmt). 2007 Oct;16(8):1145-56.

PMID:
17937567
8.

An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.

Wernicke JF, Wang F, Pritchett YL, Smith TR, Raskin J, D'Souza DN, Iyengar S, Chappell AS.

Pain Med. 2007 Sep;8(6):503-13.

PMID:
17716324
9.

Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.

Wernicke JF, Holdridge KC, Jin L, Edison T, Zhang S, Bangs ME, Allen AJ, Ball S, Dunn D.

Dev Med Child Neurol. 2007 Jul;49(7):498-502.

10.

A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.

Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, Raskin J.

Neurology. 2006 Oct 24;67(8):1411-20.

PMID:
17060567
11.

Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial.

Wernicke JF, Raskin J, Rosen A, Pritchett YL, D'Souza DN, Iyengar S, Knopp K, Le TK.

Curr Ther Res Clin Exp. 2006 Sep;67(5):283-304. doi: 10.1016/j.curtheres.2006.10.001.

12.

Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain.

Raskin J, Smith TR, Wong K, Pritchett YL, D'Souza DN, Iyengar S, Wernicke JF.

J Palliat Med. 2006 Feb;9(1):29-40.

PMID:
16430342
13.

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.

Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF.

Pain. 2005 Dec 15;119(1-3):5-15. Epub 2005 Nov 17.

PMID:
16298061
14.

A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.

Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF.

Pain Med. 2005 Sep-Oct;6(5):346-56.

PMID:
16266355
15.

Fibromyalgia syndrome.

Mease PJ, Clauw DJ, Arnold LM, Goldenberg DL, Witter J, Williams DA, Simon LS, Strand CV, Bramson C, Martin S, Wright TM, Littman B, Wernicke JF, Gendreau RM, Crofford LJ.

J Rheumatol. 2005 Nov;32(11):2270-7.

PMID:
16265715
16.

Safety and adverse event profile of duloxetine.

Wernicke JF, Gahimer J, Yalcin I, Wulster-Radcliffe M, Viktrup L.

Expert Opin Drug Saf. 2005 Nov;4(6):987-93. Review.

PMID:
16255658
17.
18.

Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.

Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF.

J Atten Disord. 2004 Oct;8(2):45-52.

PMID:
15801334
19.

QT correction methods in children and adolescents.

Wernicke JF, Faries D, Breitung R, Girod D.

J Cardiovasc Electrophysiol. 2005 Jan;16(1):76-81.

PMID:
15673393
20.

Safety and side effect profile of fluoxetine.

Wernicke JF.

Expert Opin Drug Saf. 2004 Sep;3(5):495-504. Review.

PMID:
15335304
21.

Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.

Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D.

J Clin Psychopharmacol. 2004 Feb;24(1):30-5.

PMID:
14709944
22.

Cardiovascular effects of atomoxetine in children, adolescents, and adults.

Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J.

Drug Saf. 2003;26(10):729-40. Review.

PMID:
12862507
23.

Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.

Wernicke JF, Kratochvil CJ.

J Clin Psychiatry. 2002;63 Suppl 12:50-5. Review.

24.

A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders.

Jobe PC, Dailey JW, Wernicke JF.

Crit Rev Neurobiol. 1999;13(4):317-56. Review.

PMID:
11028680
25.
26.

Vagus nerve stimulation for the treatment of medically intractable seizures. Results of a 1-year open-extension trial. Vagus Nerve Stimulation Study Group.

Salinsky MC, Uthman BM, Ristanovic RK, Wernicke JF, Tarver WB.

Arch Neurol. 1996 Nov;53(11):1176-80.

PMID:
8912492
27.

Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures.

Ben-Menachem E, Hamberger A, Hedner T, Hammond EJ, Uthman BM, Slater J, Treig T, Stefan H, Ramsay RE, Wernicke JF, et al.

Epilepsy Res. 1995 Mar;20(3):221-7.

PMID:
7796794
28.

Safety and tolerability of the implantable recurrent laryngeal nerve stimulator.

Friedman M, Wernicke JF, Caldarelli DD.

Laryngoscope. 1994 Oct;104(10):1240-4.

PMID:
7934595
29.
30.

Vagus nerve stimulation for treatment of partial seizures: 2. Safety, side effects, and tolerability. First International Vagus Nerve Stimulation Study Group.

Ramsay RE, Uthman BM, Augustinsson LE, Upton AR, Naritoku D, Willis J, Treig T, Barolat G, Wernicke JF.

Epilepsia. 1994 May-Jun;35(3):627-36.

PMID:
8026409
31.

Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group.

Ben-Menachem E, MaƱon-Espaillat R, Ristanovic R, Wilder BJ, Stefan H, Mirza W, Tarver WB, Wernicke JF.

Epilepsia. 1994 May-Jun;35(3):616-26.

PMID:
8026408
32.

Treatment of epilepsy by stimulation of the vagus nerve.

Uthman BM, Wilder BJ, Penry JK, Dean C, Ramsay RE, Reid SA, Hammond EJ, Tarver WB, Wernicke JF.

Neurology. 1993 Jul;43(7):1338-45.

PMID:
8327135
33.

Treatment of refractory partial seizures: preliminary results of a controlled study.

Holder LK, Wernicke JF, Tarver WB.

Pacing Clin Electrophysiol. 1992 Oct;15(10 Pt 2):1557-71.

PMID:
1383970
34.

Clinical experience with a helical bipolar stimulating lead.

Tarver WB, George RE, Maschino SE, Holder LK, Wernicke JF.

Pacing Clin Electrophysiol. 1992 Oct;15(10 Pt 2):1545-56.

PMID:
1383969
35.

High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression.

Beasley CM Jr, Sayler ME, Bosomworth JC, Wernicke JF.

J Clin Psychopharmacol. 1991 Jun;11(3):166-74.

PMID:
2066455
36.

Approaches for the development of oral drug therapies for erectile dysfunction.

Foreman MM, Wernicke JF.

Semin Urol. 1990 May;8(2):107-12. Review.

PMID:
2162075
37.

Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression.

Dunlop SR, Dornseif BE, Wernicke JF, Potvin JH.

Psychopharmacol Bull. 1990;26(2):173-80.

PMID:
2236453
38.

Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression.

Beasley CM Jr, Bosomworth JC, Wernicke JF.

Psychopharmacol Bull. 1990;26(1):18-24.

PMID:
2196623
39.

A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder.

Cohn JB, Collins G, Ashbrook E, Wernicke JF.

Int Clin Psychopharmacol. 1989 Oct;4(4):313-22.

PMID:
2607128
40.

Effect of dose escalation after low-dose fluoxetine therapy.

Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF.

Psychopharmacol Bull. 1989;25(1):71-9. No abstract available.

PMID:
2672072
41.

Fluoxetine at 20 mg per day: the recommended and therapeutic dose in the treatment of depression.

Wernicke JF, Bosomworth JC, Ashbrook E.

Int Clin Psychopharmacol. 1989 Jan;4 Suppl 1:63-7. No abstract available.

PMID:
2644341
42.

Placebo response in depression: a search for predictors.

Brown WA, Dornseif BE, Wernicke JF.

Psychiatry Res. 1988 Dec;26(3):259-64.

PMID:
3065807
43.

The evidence for 20mg a day of fluoxetine as the optimal dose in the treatment of depression.

Altamura AC, Montgomery SA, Wernicke JF.

Br J Psychiatry Suppl. 1988 Sep;(3):109-12. No abstract available.

PMID:
3074862
44.

Low-dose fluoxetine therapy for depression.

Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M.

Psychopharmacol Bull. 1988;24(1):183-8. No abstract available.

PMID:
3290940
45.

Fixed-dose fluoxetine therapy for depression.

Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL.

Psychopharmacol Bull. 1987;23(1):164-8. No abstract available.

PMID:
3496625
47.

The side effect profile and safety of fluoxetine.

Wernicke JF.

J Clin Psychiatry. 1985 Mar;46(3 Pt 2):59-67. Review.

PMID:
3156126
48.

A humoral lymphocyte transformation inhibition factor in multiple sclerosis.

Wernicke JF, Sweet PM, van den Noort S, Mayberg HS, Armentrout SA.

J Clin Lab Immunol. 1983 Dec;12(4):187-95.

PMID:
6198521
49.

Acid lipase-esterase (4-methylumbelliferyl oleate hydrolase) of white matter localized in oligodendrocyte cell bodies.

Hirsch HE, Wernicke JF, Myers LW, Parks ME.

J Neurochem. 1977 Dec;29(6):979-85. No abstract available.

PMID:
23413
50.

The mechanism of action of beta-bungarotoxin.

Wernicke JF, Vanker AD, Howard BD.

J Neurochem. 1975 Oct;25(4):483-96. No abstract available.

PMID:
1151385

Supplemental Content

Loading ...
Support Center